January 19, 2024 11:05 AM ESTUpdated 11:23 AM
Financing
Pharma

New­ly hope­ful, bio­phar­ma still faces an un­cer­tain 2024

Max Gelman

Senior Editor

De­spite cau­tious op­ti­mism in bio­phar­ma cir­cles about 2024, there’s emerg­ing think­ing that such sen­ti­ment is not guar­an­teed to trans­late in­to ma­te­r­i­al gains.

The Fed­er­al Re­serve …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times